DDInter90 DDInter899
Amprenavir is a protease inhibitor used to treat HIV infection.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Amprenavir {u} (Compound) resembles {v} (Compound) Darunavir
Amprenavir {u} (Compound) resembles {v} (Compound) Fosamprenavir
Amprenavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Amprenavir {u} (Compound) binds {v} (Gene) ABCB1
Amprenavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Amprenavir {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Amprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Amprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Amprenavir (Compound) resembles Darunavir (Compound)
Amprenavir (Compound) resembles Fosamprenavir (Compound)
Amprenavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Amprenavir (Compound) binds ABCB1 (Gene)
Amprenavir (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Amprenavir (Compound) causes Musculoskeletal discomfort (Side Effect)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone